Currently, only two TLR agonists are FDA approved for cancer: Bacillus Calmette-Guerin (acting as a TLR2/4 and TLR9 agonist) against non-muscle-invasive bladder cancer and imiquimod, a TLR7 agonist for superficial basal cell carcinoma.144. The gene discussed is TLR9; the disease is cancer.